PMC:7321036 / 125377-125869 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T673","span":{"begin":1,"end":2},"obj":"CL_6"},{"id":"T674","span":{"begin":4,"end":5},"obj":"SP_7"},{"id":"T679","span":{"begin":31,"end":32},"obj":"PR:000001245"},{"id":"T680","span":{"begin":48,"end":49},"obj":"GO:0010467"},{"id":"T687","span":{"begin":93,"end":94},"obj":"GO:0010467"},{"id":"T693","span":{"begin":115,"end":116},"obj":"GO:0065007"},{"id":"T697","span":{"begin":127,"end":128},"obj":"GO:0007050"},{"id":"T707","span":{"begin":151,"end":152},"obj":"BV_13"},{"id":"T710","span":{"begin":154,"end":155},"obj":"CHEBI:32958;CHEBI:32958"},{"id":"T712","span":{"begin":158,"end":160},"obj":"CHEBI:32958;CHEBI:32958"},{"id":"T717","span":{"begin":171,"end":172},"obj":"SP_7"},{"id":"T726","span":{"begin":182,"end":183},"obj":"PR:000008814"},{"id":"T728","span":{"begin":183,"end":186},"obj":"PR:000002087"},{"id":"T730","span":{"begin":186,"end":188},"obj":"GO:0065007"},{"id":"T731","span":{"begin":196,"end":197},"obj":"NCBITaxon:10239"},{"id":"T735","span":{"begin":200,"end":201},"obj":"GO:0000165"},{"id":"T740","span":{"begin":213,"end":215},"obj":"BV_27"},{"id":"T742","span":{"begin":222,"end":224},"obj":"GO:0000165"},{"id":"T746","span":{"begin":240,"end":241},"obj":"SP_7"},{"id":"T747","span":{"begin":243,"end":244},"obj":"CL_6"},{"id":"T749","span":{"begin":249,"end":250},"obj":"PR:000004986;CL_2"},{"id":"T756","span":{"begin":264,"end":265},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T758","span":{"begin":270,"end":271},"obj":"SP_7"},{"id":"T763","span":{"begin":296,"end":297},"obj":"SP_7"},{"id":"T764","span":{"begin":298,"end":299},"obj":"CL_6"},{"id":"T791","span":{"begin":353,"end":355},"obj":"SP_7"},{"id":"T796","span":{"begin":386,"end":387},"obj":"SP_7"},{"id":"T798","span":{"begin":395,"end":396},"obj":"SP_7"},{"id":"T801","span":{"begin":412,"end":413},"obj":"CHEBI:35224;CHEBI:35224"},{"id":"T804","span":{"begin":445,"end":446},"obj":"SP_6;NCBITaxon:9606"},{"id":"T805","span":{"begin":446,"end":447},"obj":"UBERON:0002048"},{"id":"T806","span":{"begin":453,"end":454},"obj":"SP_6;NCBITaxon:9606"},{"id":"T807","span":{"begin":454,"end":455},"obj":"UBERON:0000483"},{"id":"T808","span":{"begin":455,"end":457},"obj":"UBERON:0002048"},{"id":"T811","span":{"begin":465,"end":466},"obj":"UBERON:0002031;CL:0002328"},{"id":"T812","span":{"begin":470,"end":471},"obj":"GO:0065007"},{"id":"T813","span":{"begin":472,"end":473},"obj":"PR:000008220"},{"id":"T43","span":{"begin":0,"end":5},"obj":"CHEBI:36044;CHEBI:36044"},{"id":"T44","span":{"begin":10,"end":19},"obj":"CHEBI:36357;CHEBI:36357"}],"text":"Drugs and compounds mapped to top kinase activities (Table S4) and prioritized phosphorylation sites (Table S5). DrugInfo tab depicts known protein targets, approval status, SMILES, supplier, catalog numbers, chembl IDs, annotation of test site and cell line in which tests were performed, IC50 (viral inhibition) and CC50 (cell viability) values for pharmacological profiling. FullDrugResponseData tab depicts mean and standard deviation for drug screening experiments depicted in Figure S5."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T68","span":{"begin":140,"end":147},"obj":"Body_part"},{"id":"T69","span":{"begin":249,"end":253},"obj":"Body_part"},{"id":"T70","span":{"begin":324,"end":328},"obj":"Body_part"}],"attributes":[{"id":"A68","pred":"fma_id","subj":"T68","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A69","pred":"fma_id","subj":"T69","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A70","pred":"fma_id","subj":"T70","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Drugs and compounds mapped to top kinase activities (Table S4) and prioritized phosphorylation sites (Table S5). DrugInfo tab depicts known protein targets, approval status, SMILES, supplier, catalog numbers, chembl IDs, annotation of test site and cell line in which tests were performed, IC50 (viral inhibition) and CC50 (cell viability) values for pharmacological profiling. FullDrugResponseData tab depicts mean and standard deviation for drug screening experiments depicted in Figure S5."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T198","span":{"begin":41,"end":51},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T199","span":{"begin":108,"end":110},"obj":"http://purl.obolibrary.org/obo/CLO_0008933"},{"id":"T200","span":{"begin":235,"end":239},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T201","span":{"begin":249,"end":258},"obj":"http://purl.obolibrary.org/obo/CLO_0000031"},{"id":"T202","span":{"begin":268,"end":273},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T203","span":{"begin":324,"end":328},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T204","span":{"begin":489,"end":491},"obj":"http://purl.obolibrary.org/obo/CLO_0008933"}],"text":"Drugs and compounds mapped to top kinase activities (Table S4) and prioritized phosphorylation sites (Table S5). DrugInfo tab depicts known protein targets, approval status, SMILES, supplier, catalog numbers, chembl IDs, annotation of test site and cell line in which tests were performed, IC50 (viral inhibition) and CC50 (cell viability) values for pharmacological profiling. FullDrugResponseData tab depicts mean and standard deviation for drug screening experiments depicted in Figure S5."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T32084","span":{"begin":59,"end":61},"obj":"Chemical"},{"id":"T81403","span":{"begin":108,"end":110},"obj":"Chemical"},{"id":"T98259","span":{"begin":140,"end":147},"obj":"Chemical"},{"id":"T51993","span":{"begin":443,"end":447},"obj":"Chemical"},{"id":"T91938","span":{"begin":489,"end":491},"obj":"Chemical"}],"attributes":[{"id":"A82140","pred":"chebi_id","subj":"T32084","obj":"http://purl.obolibrary.org/obo/CHEBI_29401"},{"id":"A10041","pred":"chebi_id","subj":"T81403","obj":"http://purl.obolibrary.org/obo/CHEBI_29386"},{"id":"A94828","pred":"chebi_id","subj":"T98259","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A13255","pred":"chebi_id","subj":"T51993","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A96603","pred":"chebi_id","subj":"T91938","obj":"http://purl.obolibrary.org/obo/CHEBI_29386"}],"text":"Drugs and compounds mapped to top kinase activities (Table S4) and prioritized phosphorylation sites (Table S5). DrugInfo tab depicts known protein targets, approval status, SMILES, supplier, catalog numbers, chembl IDs, annotation of test site and cell line in which tests were performed, IC50 (viral inhibition) and CC50 (cell viability) values for pharmacological profiling. FullDrugResponseData tab depicts mean and standard deviation for drug screening experiments depicted in Figure S5."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T64","span":{"begin":34,"end":51},"obj":"http://purl.obolibrary.org/obo/GO_0016301"},{"id":"T65","span":{"begin":79,"end":94},"obj":"http://purl.obolibrary.org/obo/GO_0016310"},{"id":"T66","span":{"begin":140,"end":155},"obj":"http://purl.obolibrary.org/obo/GO_0006605"}],"text":"Drugs and compounds mapped to top kinase activities (Table S4) and prioritized phosphorylation sites (Table S5). DrugInfo tab depicts known protein targets, approval status, SMILES, supplier, catalog numbers, chembl IDs, annotation of test site and cell line in which tests were performed, IC50 (viral inhibition) and CC50 (cell viability) values for pharmacological profiling. FullDrugResponseData tab depicts mean and standard deviation for drug screening experiments depicted in Figure S5."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1004","span":{"begin":0,"end":112},"obj":"Sentence"},{"id":"T1005","span":{"begin":113,"end":377},"obj":"Sentence"},{"id":"T1006","span":{"begin":378,"end":492},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Drugs and compounds mapped to top kinase activities (Table S4) and prioritized phosphorylation sites (Table S5). DrugInfo tab depicts known protein targets, approval status, SMILES, supplier, catalog numbers, chembl IDs, annotation of test site and cell line in which tests were performed, IC50 (viral inhibition) and CC50 (cell viability) values for pharmacological profiling. FullDrugResponseData tab depicts mean and standard deviation for drug screening experiments depicted in Figure S5."}